Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Atar

Showing results (21-30 of 405) with videos related to

Pageof 41
Sort By:
European Heart Journal|February 7, 2007
Levosimendan: perpetuum mobile?Stefan Agewall, Dan Atar
European Journal of Internal Medicine|June 6, 2021
The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confusedAndrea Rubboli, Dan Atar
European Heart Journal|May 6, 2025
Fellow of the European Society of Cardiology: recognizing excellence in cardiologyDan Atar, Marco Roffi
European Heart Journal|February 13, 2019
On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?Dan Atar, Irene Grundvold
Cardiology|August 19, 2021
Icons in CardiologyHeinrich Taegtmeyer, Dan Atar
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 6, 2011
[New European guidelines for acute myocardial infarction]Stefan Agewall, Dan Atar
Handbook of Experimental Pharmacology|December 19, 2009
Androgenic anabolic steroid abuse and the cardiovascular systemPaul Vanberg, Dan Atar
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 13, 2017
Dan Atar, Stefan Agewall
Biomarkers in Medicine|December 8, 2010
A window into your heart: taking cardiac troponin to the next levelJonas Hallén, Dan Atar
Kardiologia Polska|June 13, 2025
Subclinical atrial fibrillation: Who benefits from oral anticoagulation?Dan Atar, Cecilia Linde
Pageof 41

Showing results (21-30 of 405) with videos related to

Sort By:
Pageof 41
European Heart Journal|February 7, 2007
Levosimendan: perpetuum mobile?Stefan Agewall, Dan Atar
European Journal of Internal Medicine|June 6, 2021
The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confusedAndrea Rubboli, Dan Atar
European Heart Journal|May 6, 2025
Fellow of the European Society of Cardiology: recognizing excellence in cardiologyDan Atar, Marco Roffi
European Heart Journal|February 13, 2019
On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?Dan Atar, Irene Grundvold
Cardiology|August 19, 2021
Icons in CardiologyHeinrich Taegtmeyer, Dan Atar
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 6, 2011
[New European guidelines for acute myocardial infarction]Stefan Agewall, Dan Atar
Handbook of Experimental Pharmacology|December 19, 2009
Androgenic anabolic steroid abuse and the cardiovascular systemPaul Vanberg, Dan Atar
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 13, 2017
Dan Atar, Stefan Agewall
Biomarkers in Medicine|December 8, 2010
A window into your heart: taking cardiac troponin to the next levelJonas Hallén, Dan Atar
Kardiologia Polska|June 13, 2025
Subclinical atrial fibrillation: Who benefits from oral anticoagulation?Dan Atar, Cecilia Linde
Pageof 41